Combination of approved immune checkpoint inhibitors has shown remarkable efficacy in the treatment of melanoma, but at the cost of high toxicity. After years of intensive research, inhibitors of the immune checkpoint molecule LAG-3 are now demonstrating promising results and favorable toxicity profiles in clinical trials in combination with inhibition of the checkpoint molecule PD-1.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy Open Access 19 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hodi, F. S. et al. N. Engl. J. Med. 363, 711–723 (2010).
Robert, C. et al. N. Engl. J. Med. 372, 2521–2532 (2015).
Robert, C. et al. N. Engl. J. Med. 372, 320–330 (2015).
Larkin, J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1910836 (2019).
Tawbi, H. A. et al. N. Engl. J. Med. 379, 722–730 (2018).
Zimmer, L. et al. Lancet 395, 1558–1568 (2020).
Blank, C. U. et al. Nat. Med. 24, 1655–1661 (2018).
Maruhashi, T., Sugiura, D., Okazaki, I. & Okazaki, T. J. Immunother. Cancer 8, e001014 (2020).
He, Y. et al. J. Thorac. Oncol. 12, 814–823 (2017).
Woo, S.-R. et al. Cancer Res. 72, 917–927 (2012).
Grosso, J. F. et al. J. Clin. Invest. 117, 3383–3392 (2007).
Huang, R.-Y. et al. Oncotarget 6, 27359–27377 (2015).
Ascierto, P. A. et al. Ann. Oncol. 28, v611–v612 (2017).
Lipson, E. J. et al. J. Clin. Oncol. 39, 9503–9503 (2021).
Amaria, R. N. et al. J. Clin. Oncol. 39, 9502–9502 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author is a consultant for Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Novartis, Roche, AstraZeneca, Pierre Fabre and Sanofi.
Rights and permissions
About this article
Cite this article
Robert, C. LAG-3 and PD-1 blockade raises the bar for melanoma. Nat Cancer 2, 1251–1253 (2021). https://doi.org/10.1038/s43018-021-00276-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00276-8
This article is cited by
-
Rational combinations of targeted cancer therapies: background, advances and challenges
Nature Reviews Drug Discovery (2023)
-
Nivolumab/relatlimab in advanced melanoma: a profile of its use
Drugs & Therapy Perspectives (2023)
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy (2022)
-
It’s a wrap for 2021!
Nature Cancer (2021)
